Skip to Content

Ryzodeg 70/30 Approval History

FDA Approved: Yes (First approved September 25, 2015)
Brand name: Ryzodeg 70/30
Generic name: insulin degludec and insulin aspart
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Diabetes, Type 1, Diabetes, Type 2

Ryzodeg 70/30 (insulin degludec and insulin aspart) is a long-acting insulin analog and rapid-acting human insulin analog combination indicated to improve glycemic control in adults with diabetes mellitus.

Development History and FDA Approval Process for Ryzodeg 70/30

DateArticle
Sep 25, 2015Approval FDA Approves Ryzodeg 70/30 (insulin degludec/insulin aspart) for Diabetes Mellitus

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide